Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

LCMS System Identifies Unknowns with Greater Certainty

By Drug Discovery Trends Editor | October 31, 2007

Shimadzu LCMS-IT-TOFShimadzu Corporation, Columbia, Md., has developed a new system featuring its award-winning LCMS-IT-TOF mass spectrometer. Using information-rich MSn data, the patent-pending Formula Predictor software takes advantage of multiple levels of fragmentation, isotope pattern verification, and unique fragment-ion filtering techniques to accurately determine the correct formula for unknown components.


Traditional approaches for deducing empirical formulae from mass spec data often depend on very high mass accuracy, which carries a correspondingly high cost, and considerable time input from the user to eliminate low-probability structures. Shimadzu’s new system reduces or eliminates this need for tedious, manual processing of target candidates. In many cases, the software can reduce the collection of target compounds from a high number of possible candidates to predicting the most likely empirical formula with just a simple mouse click, according to the company.


Shimadzu’s LCMS-IT-TOF addresses the needs of biomarker discovery, trace-amount impurity identification, and natural products research.


Features of the LCMS-IT-TOF include:



  • High mass accuracy MSn analysis. The high level of accuracy helps scientists process their data with greater confidence by performing accurate database searching and enabling workflows and data interpretation to greater precision.

  • High-sensitivity, full-spectrum TOF analyzer providing low femtomole/picogram detection of multiple components in a single analysis.

  • Constant mass accuracy and mass resolution in all MS modes.

  • Fast data acquisition, up to 10 spectra per second, for efficient peak detection and compatibility with ultrafast HPLC separations.

  • High-speed polarity switching (switching time of 100 milliseconds)



Shimadzu Scientific Instruments, Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50